Lilly’s tirzepatide shows superior weight reduction in phase 3 trial
Eli Lilly and Company (Lilly) said that tirzepatide has shown superior efficacy over placebo in chronic weight management, according to the results from the phase ... Read More
Lilly to sell hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals
Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 ... Read More
Lilly gets FDA fast track designation for tirzepatide in obesity
Eli Lilly and Company (Lilly) has been granted fast track designation for tirzepatide from the US Food and Drug Administration (FDA) for the treatment of ... Read More